Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reduced Intensity Conditioning for HSCT in Immune Function Disorders
NCT01821781Phase 2Completed
- Sponsor
- Washington University School of Medicine
- Start
- Apr 2013
- Primary completion
- May 2025
- Modality
- Monoclonal Antibodies, Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of alemtuzumab, fludarabine, thiotepa and melphalan in immunodeficiency disorder, severe combined immunodeficiency (SCID), chronic granulomatous disease (CGD) and 11 more, sponsored by Washington University School of Medicine. Primary endpoint: Number of Participants With Donor Engraftment at 1 year. Started Apr 2013; status: completed.
02
Drugs
alemtuzumabfludarabinethiotepamelphalan
03
Conditions
immunodeficiency disordersevere combined immunodeficiency (SCID)chronic granulomatous disease (CGD)X-linked agammaglobulinemia (XLA)Wiskott-Aldrich syndrome (WAS)
Beyond the preview
Go deeper on NCT01821781.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01821781.